VIR BIOTECHNOLOGY INC (VIR) Stock Price, Quote, News and Overview
NASDAQ:VIR - Nasdaq - US92764N1028 - Common Stock - Currency: USD
VIR Quote, Performance and Key Statistics
VIR BIOTECHNOLOGY INC
NASDAQ:VIR (1/24/2025, 6:04:30 PM)
After market: 10.57 -0.06 (-0.56%)10.63
-0.57 (-5.09%)
The current stock price of VIR is 10.63 USD. In the past month the price increased by 44.82%. In the past year, price increased by 11.31%.
VIR Latest News, Press Releases and Analysis
Top movers in Wednesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's take a look at the stocks that are in motion in today's session.
What's going on in today's session
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
These stocks are moving in today's pre-market session
Get insights into the top gainers and losers of Wednesday's pre-market session.
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
VIR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About VIR
Company Profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 587 full-time employees. The company went IPO on 2019-10-11. The firm's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The firm's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. The company also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Company Info
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158 US
CEO: George Scangos
Employees: 587
Company Website: https://www.vir.bio/
Investor Relations: https://investors.vir.bio/
Phone: 14159064324
VIR FAQ
What is the stock price of VIR?
The current stock price of VIR is 10.63 USD.
What is the symbol for VIR BIOTECHNOLOGY INC stock?
The exchange symbol of VIR BIOTECHNOLOGY INC is VIR and it is listed on the Nasdaq exchange.
On which exchange is VIR stock listed?
VIR stock is listed on the Nasdaq exchange.
Is VIR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VIR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VIR.
Does VIR stock pay dividends?
VIR does not pay a dividend.
When does VIR stock report earnings?
VIR will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of VIR?
VIR does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.92).
What is the Short Interest ratio of VIR stock?
The outstanding short interest for VIR is 5.6% of its float.
VIR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VIR. When comparing the yearly performance of all stocks, VIR is one of the better performing stocks in the market, outperforming 85.04% of all stocks.
VIR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to VIR. VIR has a great financial health rating, but its profitability evaluates not so good.
VIR Financial Highlights
Over the last trailing twelve months VIR reported a non-GAAP Earnings per Share(EPS) of -3.92. The EPS increased by 12.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.6% | ||
| ROE | -42.99% | ||
| Debt/Equity | 0 |
VIR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to VIR. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 13.59% and a revenue growth -12.53% for VIR